CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Molecular Testing for the Management of Pancreatic Cysts and Solid Pancreaticobiliary Lesions

This policy governs coverage of the PathfinderTG (PancraGEN) molecular test as a second-line diagnostic supplement for evaluation of pancreatic cysts and solid pancreaticobiliary lesions for Blue Cross Blue Shield - Rhode Island members, including Medicare Advantage and Commercial products.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyMolecular Testing for the Management of Pancreatic Cysts and Solid Pancreaticobiliary Lesions

Policy CodePolicy N/A

Change TypeRoutine review — no material changes

Effective Date07/01/2025

Next Review DateN/A

Key ActionObtain prior authorization (required for Medicare Advantage; recommended for Commercial) and document that first-line diagnostics were inconclusive and the test will influence surgical vs non-surgical management.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

PathfinderTGspecified proprietary test covered with criteria

Requiredprior authorization

Unlisted CPTsreporting codes

Clinical record requireddocumentation

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for PathfinderTG (PancraGEN)

Medical necessity criteria for PathfinderTG

Covered when ALL of the following are met

Primary coverage criteria: 1) A concise affirmation documented in the medical record that a decision regarding treatment has not already been made and that the results of the molecular evaluation will assist in determining if more aggressive treatment (e.g., surgery) is necessary; 2) A comprehensive first-line diagnostic evaluation (for example cyst cytopathology, radiographic assessment, and/or cyst fluid CEA) has been performed and remains inconclusive — e.g., cytopathology or imaging raises suspicion but is not definitive, or cyst fluid CEA is suggestive of a mucinous cyst but not diagnostic; 3) The PathfinderTG (PancraGEN) test is being used selectively as an occasional second-line diagnostic supplement to resolve clinical uncertainty regarding malignancy or malignant potential and the results are expected to influence the choice between surgical versus non-surgical management.

Applicable to PathfinderTG (PancraGEN) for pancreatic cyst or pancreatic mass evaluations only

Not covered indications

Not covered: All PathfinderTG indications other than pancreatic cyst fluid evaluation (and related pancreatic cyst/mass evaluations meeting the above criteria) are considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products due to insufficient evidence of clinical benefit.

Applies to non-pancreatic and other non-specified uses of PathfinderTG

Some Commercial member contracts may specifically exclude certain genetic testing services under the state Biomarker Testing mandate. Coverage for PathfinderTG may therefore vary by funded group; refer to the member's Benefit Booklet and the related Biomarker Testing Mandate policy to determine whether the test is covered, not medically necessary, or contractually excluded.

PathfinderTG indications other than evaluation of pancreatic cyst fluid are considered not medically necessary for Commercial Products due to insufficient evidence. This policy restricts coverage to pancreatic cyst/mass evaluations only and does not support other clinical uses of PathfinderTG for Commercial lines of business.

Covered Indications

Coding and Test Codes

Unlisted CPT CodesCPT

84999	Unlisted chemistry procedure (used where no established CPT adequately describes the procedure)
81479	Unlisted molecular pathology procedure

Cyst fluid carcinoembryonic antigen (CEA) — threshold information

CEA thresholdCEA greater than or equal to 192 ng/mL (document cites a CEA threshold indicative of mucinous cyst)

Use contextCEA level referenced as part of first-line diagnostics when cytology or radiography raise suspicion but are not definitive

Role in decision-makingAn elevated CEA (>=192 ng/mL) may suggest a mucinous cyst but is not diagnostic alone; used to determine need for second-line molecular testing

Provider Actions, Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for Medicare Advantage Plans and is recommended for Commercial Products. Participating providers must obtain authorization via the payer's online tool. Only the ordering physician may request authorization; laboratories and laboratory representatives are not permitted to obtain authorizations, participate in the authorization process, or act on behalf of the ordering physician. Services rendered without appropriate prior authorization may be denied and billed to the performing laboratory when applicable.

Prior authorization obtained via payer online tool for participating providers
Only the ordering physician may request or appeal authorizations — laboratories are not allowed to obtain authorization or participate
Services without prior authorization may be denied and will not be charged to the member if the laboratory failed to obtain authorization

Step Therapy

Step Therapy / Sequencing

Coverage for second-line molecular testing (PathfinderTG) for pancreatic cyst/mass is contingent upon completion of first-line diagnostic evaluation with documented inconclusive results that leave clinical management (surgical vs non-surgical) uncertain. The patient's medical record must clearly explain why first-line diagnostics were insufficient and how the molecular test result will influence management.

Not Covered Services

For Medicare Advantage Plans, all PathfinderTG indications other than pancreatic cyst fluid evaluation are NOT COVERED. For Commercial Products these non–pancreatic cyst indications are considered not medically necessary because current evidence is insufficient to demonstrate clinical benefit.

Eligibility Requirements

Eligibility for PathfinderTG testing requires documentation in the medical record that the test will influence a current treatment decision and that a decision about definitive management has not already been made. The record must show that a comprehensive first-line diagnostic evaluation (for example, cyst cytopathology, radiographic assessment, or cyst fluid CEA) was performed and remained inconclusive, and that second-line molecular testing is expected to meaningfully inform the choice between surgical and non-surgical management.

Medical record documentation must be legible, include patient identification and the treating clinician's signature, clearly state the purpose of the PathfinderTG test, support the selected ICD-10-CM and CPT/HCPCS codes, and explicitly describe why first-line diagnostics were insufficient such that this specialized second-line test is necessary.

Background

Pancreatic cysts are fluid‑filled, cell‑lined structures commonly representing mucinous lesions (for example, intraductal papillary mucinous neoplasms) that carry variable malignant potential and are monitored because of the risk of malignant transformation. Solid pancreatic masses have a broad differential diagnosis. When standard pathologic and radiographic evaluations are inconclusive, topographic genotyping (PathfinderTG/PancraGEN) integrates microdissection with molecular analysis to assess mutational profiles and may serve as a second-line diagnostic supplement to reduce diagnostic uncertainty and help guide surgical versus non‑surgical management decisions.

Definitions

Topographic genotyping / PathfinderTG (PancraGEN) — definition and brief description

DefinitionTopographic genotyping (PathfinderTG/PancraGEN) is a patented molecular anatomic pathology method that analyzes microdissected tissue for mutational profiles, usable on minute needle biopsy specimens and archived paraffin samples

PurposeIntended as a second-line diagnostic supplement to aid pathologic diagnosis when first-line analyses (cytology, radiography, cyst fluid tests) are inconclusive

Specimen requirementsCan be performed on tissue specimens of any size, including minute needle biopsy specimens and long‑term paraffin‑embedded samples

Provider / regulatory noteAvailable through Interpace Diagnostics (PancraGEN); laboratory‑developed tests must meet CLIA high‑complexity requirements

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyMolecular Testing for the Management of Pancreatic Cysts and Solid Pancreaticobiliary Lesions

Policy CodePolicy N/A

Change TypeRoutine review — no material changes

Effective Date07/01/2025

Next Review DateN/A

SourceLink

On This Page

First-line diagnostics (e.g., cytopathology, radiographic evaluation, cyst fluid CEA) must have been performed and shown inconclusive or insufficient to guide management
Documentation must state that results of molecular testing will assist in deciding more aggressive versus conservative treatment

Documentation Required

Medical Record Documentation

All pages of the medical record must be legible, include patient identification (e.g., full name, dates of service), and contain the legible signature of the responsible clinician. The record must be maintained and made available upon request and must support the selected ICD-10-CM and CPT/HCPCS codes. Documentation must indicate the purpose of the PathfinderTG test and demonstrate medical necessity per this policy.

Every page legible with patient identifiers and dates of service
Legible signature of the physician or non-physician practitioner responsible for care
Medical record must support ICD-10-CM and CPT/HCPCS coding and clearly indicate the purpose of the PathfinderTG test
Documentation must explain why first-line diagnostics were inadequate and justify the need for second-line molecular testing

Denial Risk

Authorization / Denial Risk

If authorization requirements are not followed or if a laboratory or third party attempts to obtain authorization on behalf of the ordering physician, BCBSRI will consider this a violation and may impose sanctions up to termination from the provider network. Laboratories that provide services without required authorization may have claims denied and be financially liable for the service.

Laboratories may not obtain authorizations or participate in authorization/appeal processes on behalf of the ordering physician
Use of a laboratory or third party to obtain authorization is a policy violation and may result in sanctions, including network termination
Unlisted CPT codes used for services without a specific code require authorization to determine coverage/medical necessity

Note

Provider Action: Ordering Physician Responsibility

Only the ordering physician may obtain prior authorization and manage related appeals or administrative processes. Laboratories are prohibited from initiating or facilitating authorization or appeals on behalf of ordering physicians. Providers must ensure authorization is secured before ordering specialized molecular testing.

Only the ordering physician may obtain authorization and pursue appeals
Laboratories and their representatives are prohibited from obtaining authorizations or participating in the authorization process
Providers must secure authorization for Unlisted CPT codes to identify the specific service and coverage determination